Renal therapeutics: patent highlights January to June 2003.
Drug-related patents with relevance to renal therapy that were published during the first half of 2003 were identified by searching Current Drugs' Patent fast-alert, evaluated for their relevance, and the most potentially significant of these documents are discussed in this review. Of the 19 documents that are analyzed in depth in this review, two related to renal cell carcinoma, three each to diabetic nephropathy, renal failure and/or allograft preservation or fibrosis, and four to inhibitors of angiotensin-converting enzyme or dipeptidylpeptidase IV, while only two identified potentially novel drug targets for renal therapy. The low number of patents with direct and substantial relevance for renal therapies indicates that kidney diseases are receiving relatively little attention from drug developers, in spite of their substantial impact on public health.
Mucke
Hermann A
HA
HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria. office@hmpharmacon.com
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000201:enzymology; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D005355:Fibrosis / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000201:enzymology; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000201:enzymology; D015394:Molecular Structure; D010330:Patents as Topic; D004364:Pharmaceutical Preparations / Q000737:chemistry; D051437:Renal Insufficiency / Q000188:drug therapy / Q000201:enzymology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations; D018819:Dipeptidyl Peptidase 4